Abstract: Trimethylamine N-oxide(TMAO) is an important gut microbiota-dependent metabolite.Currently many clinical studies have confirmed the correlation between TMAO and the prognosis of chronic kidney disease(CKD) patients.This review summarized the latest researches of TMAO on the quality-of-life and mortality of CKD over the past decade.Finally the therapeutic strategy of reducing the plasma TMAO level was elaborated for preventing the further development of CKD and improving its survival rate.